

# Personal Experience (off label Use): A New Therapeutic Tool in Various Severe Intoxications



**Prof Patrick Honoré, MD, PhD-Intensivist-Nephrologist, Co-Director of ICU**

**CHU Brugmann University Hospital**

**DMC**

**CHU Brugmann (Reine Astrid)**



**Paracelsus (1493-1541)**  
**'Grandfather of Toxicology'**

**"All things are poison and  
nothing is without poison,  
only the dose permits  
something not to be  
poisonous."**


**“The dose makes the poison”**



# The CytoSorb Adsorber



- Highly biocompatible, porous polymer beads
- Removal of hydrophobic substances due to
  - physicochemical properties
  - pore size



## Adsorption






Fig. 3. Adsorption corresponds to the saturable fixation of some molecules directly on a sorbent or a membrane along an affinity gradient depending on ionic, hydrophobic, and van der Waals interactions.

# CytoSorb set-up




Hemoperfusion



CRRT


Pre Filter

Post Filter





Extracorporeal Circuit


CPB



ECMO



# Adsorber performance - size selectivity



Dialysis

No elimination of immuno-globulins:

IgG:	150 KD
IgM:	971 KD
IgE:	198 KD
IgA:	Monomer: 160 KD
	Dimer: 385 KD
IgD:	172 KD

# The Surface Defines the Performance

## Membrane-Filter

Overall surface  
 $\cong 2\text{m}^2$



## CytoSorb® – Adsorber

Overall surface  
 $\cong 45.000\text{m}^2^*$




Medication			
Amiodarone		No	Antiarrhythmic agent [D]
Digoxin		Yes	Cardiac glycoside [D]
Amlodipine		Yes	Calcium channel blocker [D, P]
Verapamil		Yes	Calcium channel blocker [D]
Diazepam		Yes	Benzodiazepine [D]
Amitriptyline		Yes	Antidepressant [D]
Quetiapin		Yes	Antipsychotic [P, D]
Venlafaxine		Yes	Antidepressant [C, P]
Heparin		No	Anticoagulant [P]
Ticagrelor		Yes	Platelet aggregation inhibitor [D]
Rivaroxaban		Yes	Anticoagulant (Direct factor Xa inhibitor) [D]
Dabigatran		Yes	Anticoagulant (Direct thrombin inhibitor) [D]

# REMOVAL CAPABILITY OF CYTOSORB HEMADSORPTION COLUMNS FOR SELECTED PRESCRIPTION DRUGS FREQUENTLY RELATED TO DRUG OVERDOSE

Andreas Körtge<sup>1</sup>, Steffen Mitzner<sup>1,2</sup>, Reinhold Wasserkort<sup>1</sup>

<sup>1</sup>Fraunhofer Institute for Cell Therapy and Immunology IZI, Extracorporeal Immunomodulation Unit EXIM, Rostock, Germany

<sup>2</sup>Division of Nephrology, Centre for Internal Medicine, University Medicine Rostock, Rostock, Germany



presented at ESAO  
congress 2017,  
Vienna




# Removal of Ca – channel blockers-Ex Vivo Studies

## Abstract:

### A Novel Adsorbent System Rapidly Clears Amlodipine from Human Blood

Vincent J Capponi\*, Wendell T Young\*, Eric J Lavonas\*\*, Phillip P Chan\*

CRRT  
San Diego 2017




iver, CO

by current  
ial hemofusion.

### A Novel Adsorbent System Rapidly Clears Verapamil from Human Blood

Vincent J Capponi\*, Wendell T Young\*, Eric J Lavonas\*\*, Phillip P Chan\*



Whole blood samples were collected and analyzed for amlodipine concentration using liquid chromatography-mass spectrometry. Two experiments were performed.

\*Cyt  
Abst  
Back  
extra  
Cyto  
mark  
Obj  
clear  
Meth  
blood  
Mast  
arm,  
Who  
and

ent  
perfusion.  
oved and  
:an efficiently  
whole human  
Cole-Parmer  
an experimental  
the circuit.  
g equilibration,  
an blood

verapamil concentrations were determined using previously-validated ultra performance

# REMOVAL CAPABILITY OF CYTOSORB HEMADSORPTION COLUMNS FOR SELECTED PRESCRIPTION DRUGS FREQUENTLY RELATED TO DRUG OVERDOSE

Andreas Körtge<sup>1</sup>, Steffen Mitzner<sup>1,2</sup>, Reinhold Wasserkort<sup>1</sup>

<sup>1</sup>Fraunhofer Institute for Cell Therapy and Immunology IZI, Extracorporeal Immunomodulation Unit EXIM, Rostock, Germany

<sup>2</sup>Division of Nephrology, Centre for Internal Medicine, University Medicine Rostock, Rostock, Germany

JACC: BASIC TO TRANSLATIONAL SCIENCE


© 2017 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

## PRECLINICAL RESEARCH


## Ticagrelor Removal From

George O. Angheloiu, MD,<sup>a,b,c</sup> Gabriel B. Gugiu, PhD,<sup>d</sup> Cristi Ramachandra R. Dasari, PhD,<sup>a</sup> Carl Whatling, PhD<sup>f</sup>

**FIGURE 1** Experimental Setup for Ticagrelor Removal From BSA Solution and Human Blood



**FIGURE 4** Removal Rate of Ticagrelor From Whole Human Blood and Plasma



Removal rate of ticagrelor from whole human blood (A) and plasma (B) freshly (<60-min interval until being used) collected during model 3 of the blood recirculating experiment using CytoSorb.

# REMOVAL CAPABILITY OF CYTOSORB HEMADSORPTION COLUMNS FOR SELECTED PRESCRIPTION DRUGS FREQUENTLY RELATED TO DRUG OVERDOSE

Andreas Körting<sup>1</sup>, Steffen Mitzner<sup>1,2</sup>, Reinhold Wasserkort<sup>1</sup>

<sup>1</sup>Fraunhofer Institute for Cell Therapy and Immunology IZI, Extracorporeal Immunomodulation Unit EXIM, Rostock, Germany

<sup>2</sup> Division of Nephrology, Centre for Internal Medicine, University Medicine Rostock, Rostock, Germany




Table 7 Initial and equilibrium concentrations of the Rivaroxaban experiments with the calculated relative removal of the substance from the plasma and the total adsorbed mass per adsorbent mass.


Initial concentration (µg/L)	Equilibrium concentration (µg/L)	Removal (%)	Total adsorbed mass (µg/g)
46.2	20.75	55.1	0.42
145.0	21.60	85.1	2.06
571.0	37.1	93.5	8.90

# REMOVAL CAPABILITY OF CYTOSORB HEMADSORPTION COLUMNS FOR SELECTED PRESCRIPTION DRUGS FREQUENTLY RELATED TO DRUG OVERDOSE

Andreas Körtge<sup>1</sup>, Steffen Mitzner<sup>1,2</sup>, Reinhold Wasserkort<sup>1</sup>

<sup>1</sup>Fraunhofer Institute for Cell Therapy and Immunology IZI, Extracorporeal Immunomodulation Unit EXIM, Rostock, Germany

<sup>2</sup>Division of Nephrology, Centre for Internal Medicine, University Medicine Rostock, Rostock, Germany




# REMOVAL CAPABILITY OF CYTOSORB HEMADSORPTION COLUMNS FOR SELECTED PRESCRIPTION DRUGS FREQUENTLY RELATED TO DRUG OVERDOSE

Andreas Körtge<sup>1</sup>, Steffen Mitzner<sup>1,2</sup>, Reinhold Wasserkort<sup>1</sup>

<sup>1</sup>Fraunhofer Institute for Cell Therapy and Immunology IZI, Extracorporeal Immunomodulation Unit EXIM, Rostock, Germany

<sup>2</sup>Division of Nephrology, Centre for Internal Medicine, University Medicine Rostock, Rostock, Germany



## Venlafaxine intoxication with development of takotsubo cardiomyopathy: successful use of extracorporeal life support, intravenous lipid emulsion and CytoSorb®.

Schroeder J<sup>1</sup>, Zoller M<sup>1</sup>, Angstwurm M<sup>2</sup>, Kur F<sup>3</sup>, Frey L<sup>1</sup>.

**Young female patient**

**18 g of venlafaxine (240 times the daily therapeutic dose)**


- **Severe cardiomyopathy in a Takotsubo distribution**
- **Cardiogenic shock**
- **MODS**

**Treatment:**

- **Intravenous lipid emulsion**
- **Extracorporeal life support**
- **CytoSorb**

**Outcome:**

**Patient was transferred to the department of psychiatry three weeks after onset of symptoms without somatic residuals**



**Fig. 1** - Timeline showing the key therapeutic interventions during the first 3 days after intoxication with venlafaxine (figure not to scale). Intravenous lipid emulsion (ILE) was started 12 hours after intoxication. Extracorporeal life support (ECLS) was started 13 hours after intoxication. Continuous renal replacement therapy (CRR) was started 17 hours after intoxication. CytoSorb® was started 32 hours after intoxication. Blood samples for venlafaxine concentration were taken 11 hours and 42 hours after intoxication.

# Case Report

---

---

- Lady of 55 years .
- Suicide by massive intake of Tofranil (Imipramine).
- Initial Dosage show  $> 2,100$  mcg/L (Lipophilic Drug)
- Toxic over 500 and lethal  $> 1,000$  mcg/L
- QRS was enlarged up 180 millisecc
- Lactate to reduce QRS enlargement
- Intubation (GCS of 6/15).
- Shock :7 Liters of cristalloids in the first 24 hours
- PiCCO monitoring.
- Echo : EF 10 % (Cardiogenic Shock)

# Case Report

---

---

- Worsening Shock 2 mcg/kg/min NA ,Dobu15 mcg/kg/min – Adre :1 mcg/kg/min ...
- VT, VF, Torsades de pointe.Defibrillations.
- CI with the PiCCO was 0.3 L/min/M<sup>2</sup>.Cardiac Massage Started.
- Urgent Insertion of VA-ECMO - Femoral access (Flow of 3.5 L/min-Gasflow of 6 )
- Rapid improvement :inotropes could be wean (within 1 hour) -Remaining NA about 0.4 mcg/kg/min.
- Back flow inserted for the VA-ECMO in the left groin.



# Case Report

---

---

- CVVH (Oligiuria and Rhabdomyolysis) with Cytosorb started within 8 hours.
- Received 3 Cytosorb that were changed every 24 hours.
- Persisting deep coma without sedation (GCS of 3/15) and with myoclonias due to possible brain hypoxia. Bad prognosis.
- Imipramine level went down to 350 mcg/L (<500) at D 4
- VA-ECMO went out at D4 (normal Echo). Lung Improved.
- Ischemia of left limb ; operated for arterial bypass at D 4 with 3 Fasciotomies (Severe Rhabdomyolysis)
- Woke up completely at day 6 with a GCS of 15/15 but was still in MODS with AKI.

# Case Report

---

---

- Improvement of the left lower limb at D 10
- The fasciotomies were closed at D 10
- Extubation at D 10
- CVVH was stopped at D 14
- Right lower pneumonia due to influenza infection. Tamiflu and high nasal flow oxygen
- She was discharged at D 16 to the normal ward.
- At D 25 back home and can walk by herself.

# Conclusions – Take home messages

---

- 1) **Cytosorb safety (> 50,000 applications, no adverse events), effective in removing inflammatory mediators , easy to use...**
- 2) **Removal of highly albumin bounded drugs with high Vd**
- 3) **Concentration dependent: Right Timing!**
- 3) **Removal of different drugs is possible: Antidepressors (Venlafaxine, Tricyclic antidepressant, Cardiac Glycoside (Digoxin), Platelet aggregation inhibitors (Ticagrelor) NOACs (Rivaroxaban; Dabigatran), Calcium Channel Blockers (Verapamil, Amlodipine)**
- 4) **Can be Life Saving under these conditions**